Europes largest scientific conference about rheumatic diseases.

Related StoriesFDA grants accelerated approval for Tagrisso to treat sufferers with advanced NSCLCStudy shows rare HER2 missense mutations do not spread breast cancer on their ownNo progression in joint harm in 84 percent of psoriatic arthritis patientsThese data provide evidence that delayed onset of therapy with vidofludimus works well in suppressing immunopathology and autoimmune cells damage of MRLlpr/lpr mice.The findings of this trial apply to a little group of carefully screened small children with frequent wheezing episodes triggered by upper respiratory tract infections, no intercurrent symptoms or suspected allergy, and recent severe or moderate episodes. Just 17 percent of the children we screened fulfilled our selection criteria. Most participants were 1 to three years of age; in the preceding 12 months they had received, on average, two courses of systemic corticosteroids, and half the small children had been hospitalized.